ストックスクリーナーアプリを入手
5.68
1.97%
0.11
Verastem Inc (VSTM) 最新ニュース
Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's Cancer - Marketscreener.com
Can This New Ovarian Cancer Drug Transform Treatment? Key Data Reveals Breakthrough Potential - StockTitan
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN
When the Price of (VSTM) Talks, People Listen - Stock Traders Daily
Financial Snapshot: Analyzing Verastem Inc (VSTM)’s Key Ratio Metrics - The Dwinnex
Verastem Inc (NASDAQ: VSTM) Shares Fall By -4.77 Percent In The Past Week, But How Long Will It Last? - Marketing Sentinel
The time has not yet come to remove your chips from the table: Verastem Inc (VSTM) - SETE News
Recent Insider Activity Could Benefit Verastem Inc (VSTM) - Knox Daily
Verastem CEO Dan Paterson sells shares worth $4,890 - MSN
Verastem CEO Dan Paterson sells shares worth $4,890 By Investing.com - Investing.com Canada
Verastem, Inc. (NASDAQ:VSTM) Shares Acquired by JPMorgan Chase & Co. - Defense World
Verastem (NASDAQ:VSTM) Given New $9.00 Price Target at B. Riley - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Sees Large Increase in Short Interest - MarketBeat
Financial Metrics Check: Verastem Inc (VSTM)’s Ratios for Trailing Twelve Months - The Dwinnex
B. Riley Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World
Brokerages Set Verastem, Inc. (NASDAQ:VSTM) PT at $13.38 - MarketBeat
Vanguard Group Inc. Increases Stake in Verastem Inc. - GuruFocus.com
Verastem price target raised to $9 from $7 at B. Riley - MSN
B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating -January 31, 2025 at 09:19 am EST - Marketscreener.com
Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Yahoo Finance
Verastem Exercises Option for VS-7375 Targeting RAS Pathway Driven CancersVerastem, Inc. (NASDAQ:VSTM) has announced the exercise of its option with regards to VS-7375, which is an oral and selective KRAS G12D (ON/OFF) inhibitor. This move signif - Defense World
Guggenheim Reiterates Buy Rating for Verastem (NASDAQ:VSTM) - Defense World
Verastem's (VSTM) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Mizuho maintains Verastem stock outperform with $9 target By Investing.com - Investing.com Australia
Mizuho maintains Verastem stock outperform with $9 target - MSN
Cantor Fitzgerald Estimates Verastem FY2025 Earnings - Defense World
Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL
Cantor Fitzgerald Forecasts Verastem FY2025 Earnings - MarketBeat
Verstem avutometinib and defactinib combo gains FDA priority review - Seeking Alpha
Verastem Expands Oncology Pipeline with VS-7375 Acquisition - TipRanks
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
Barclays PLC Acquires 47,094 Shares of Verastem, Inc. (NASDAQ:VSTM) - MarketBeat
KRAS Inhibitors Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines - Barchart
Verastem appoints new COO with extensive biotech experience By Investing.com - Investing.com South Africa
Verastem appoints new COO with extensive biotech experience - Investing.com India
Verastem Appoints Matthew E. Ros as COO - TipRanks
Verastem Secures $150 Million Note Purchase Agreement with Oberland Capital - Defense World
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):